Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lixte Biotechnology Holdings Inc
Other Long-Term Assets
Lixte Biotechnology Holdings Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$10.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$6.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$12.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
35%
|
CAGR 10-Years
64%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$5.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
Lixte Biotechnology Holdings Inc
Glance View
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
